Mukka Proteins Q1 FY27 profit jumps 11x on margin

Results approved for quarter ended June 30, 2026

Mukka Proteins Limited said its Board of Directors approved the unaudited consolidated financial results for the quarter ended June 30, 2026 on August 12, 2026. The company reported a sharp year-on-year rise in profitability alongside strong revenue growth. Consolidated profit after tax (PAT) was reported at ₹18.63 crore for Q1 FY27, compared with ₹1.59 crore in the corresponding quarter last year. Consolidated revenue from operations rose to ₹474.80 crore from ₹164.88 crore. The company also reported an improvement in operating profitability, with EBITDA margin expanding to 10.1% from 8.49%.

Consolidated profit rises sharply year-on-year

For Q1 FY27, Mukka Proteins reported consolidated PAT of ₹18.63 crore, versus ₹1.59 crore in Q1 FY26. The company also reported total comprehensive income of ₹19.66 crore for the quarter. In another results summary included in the same information set, net income was stated at ₹18.89 crore compared with ₹1.52 crore a year earlier, and basic earnings per share (EPS) was listed at ₹0.63 versus ₹0.05. Across the disclosures, the consistent theme was a steep jump in profitability compared with the year-ago quarter.

Revenue growth drives the quarter

On the topline, consolidated revenue from operations increased to ₹474.80 crore in Q1 FY27 from ₹164.88 crore in Q1 FY26. The company reported other operating income of ₹14.85 crore, taking total revenue from operations to ₹489.65 crore. Another line item in the provided results stated total income at ₹491.25 crore for the quarter. The corresponding consolidated total revenue for Q1 FY26 was stated at ₹170.77 crore.

EBITDA expands and margin improves to 10.1%

Mukka Proteins reported consolidated EBITDA of ₹47.90 crore for Q1 FY27, compared with ₹14.50 crore in the prior-year period. The EBITDA margin expanded to 10.1% from 8.49% year-on-year. The company attributed the margin improvement to improved operational efficiency alongside topline growth. The margin change is notable because it came in the same quarter as a large scale-up in revenue.

Standalone performance: PAT at ₹19.41 crore

Alongside consolidated numbers, the company also disclosed standalone results for Q1 FY27. Standalone PAT was ₹19.41 crore, up from ₹1.14 crore year-on-year. Standalone revenue from operations was reported at ₹392.71 crore. Standalone total income was stated at ₹408.16 crore, and standalone basic EPS was ₹0.66.

Key numbers at a glance

The table below summarises the key consolidated financial metrics cited for Q1 FY27 versus Q1 FY26.

Growth rates highlighted in the release

The company’s disclosures also quantified the year-on-year expansion rates for the quarter. Consolidated revenue from operations for Q1 FY27 was stated as a 187.9% increase from Q1 FY26. Consolidated PAT for Q1 FY27 was stated as a 1074.6% increase from Q1 FY26. These growth rates mirror the sharp rise visible in the reported absolute numbers.

Board actions: NCD cancellation and strategic investment

Apart from results, the information set also referred to two board-level decisions. It stated that the board cancelled a ₹75 crore NCD issuance. It also said Mukka Proteins made a strategic investment of ₹0.65 crore (₹64.92 lakh) in Swachha Eco Solutions for a 25.98% stake. These items were presented alongside the earnings update.

Market context: share price and recent metrics cited

A share price reference in the provided information said Mukka Proteins was at ₹26.04 on August 13, 2026 at 09:33 AM. Another snippet in the same compilation referenced a current share price of ₹24.18. The same set of notes also stated EPS of ₹0.63 for the quarter ended June 2026 and EPS of 1.74 for the financial year 2025-26.

Longer-term performance snapshot from FY25 to FY26

The provided data also included full-year comparisons for FY26 versus FY25. Mukka Proteins reported revenue of ₹1,478.13 crore in FY26 versus ₹1,021.54 crore in FY25. Operating profit was ₹75.14 crore in FY26 versus ₹60.27 crore in FY25. Net profit was ₹57.09 crore in FY26 versus ₹48.10 crore in FY25. These figures provide context to the company’s quarterly momentum going into Q1 FY27.

Why the Q1 FY27 result matters

The Q1 FY27 outcome combines three changes that investors typically track closely in earnings season: higher revenue, higher operating profit, and a better margin. Revenue growth from ₹164.88 crore to ₹474.80 crore indicates a large expansion in scale versus the same quarter last year. The rise in EBITDA margin to 10.1% suggests that operating profitability improved rather than being diluted by growth. And the surge in PAT to ₹18.63 crore shows that the operating gains translated into bottom-line growth during the quarter.

Conclusion

Mukka Proteins’ Q1 FY27 results, approved on August 12, 2026, showed a sharp rise in consolidated profitability with revenue growth and EBITDA margin expansion to 10.1%. Alongside earnings, the company disclosed the cancellation of a ₹75 crore NCD issuance and an investment of ₹0.65 crore for a 25.98% stake in Swachha Eco Solutions. Investors will now track subsequent quarterly updates for continuity in revenue scale, operating margin, and any further corporate actions disclosed by the board.